Richard E. Gilbert

Richard Gilbert is Professor of Medicine at the University of Toronto, Canada Research Chair in Diabetes Complications and Head of the Division of Endocrinology at St. Michael’s Hospital in Toronto.  Dr. Gilbert has published over 230 peer-reviewed manuscripts, has numerous patents, is frequently invited as a keynote speaker at major international conferences, and co-founded Fibrotech, a biotechnology company that has brought novel anti-fibrotic therapies from the bench to early phase human trials.  Following Fibrotech’s acquisition in 2014, Dr. Gilbert then founded another biotech company, Fibrocor Therapeutics, where he served as its Chief Scientific Officer designing and overseeing research projects that lead to the development of new therapies for the prevention and treatment of diseases of fibrosis such as cirrhotic liver disease, pulmonary fibrosis, chronic kidney disease and heart failure. In November 2024, Dr. Gilbert left Fibrocor, to returned not only to conduct his own independent research but to also use his expertise to found Matrilex, a service provider that focusses on translational preclinical animal models.

Other Appointments & Affiliations

• Staff Physician, Department of Medicine, Division of Endocrinology, St. Michael's Hospital
• Professor, Department o Medicine, University of Toronto